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Introduction: Leptomeningeal carcinomatosis (LMC) from non–small-
cell lung cancer (NSCLC) is a clinically important neurological compli-
cation in the era of epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs). The purpose of this study was to compare the 
efficacy of gefitinib and erlotinib for control of LMC in NSCLC.
Methods: We retrospectively reviewed medical records of 25 EGFR 
TKI–treated NSCLC patients with LMC between 2004 and 2012 at 
Seoul National University Hospital. Cytologic negative conversion 
was defined as absence of malignant cells in the cerebrospinal fluid 
three times in succession. Cytologic conversion rates were compared 
between the gefitinib arm and the erlotinib arm.
Results: Nine patients had exon 21 point mutations and eight 
patients had exon 19 deletional mutations. Nine of 25 patients had 
already used EGFR TKIs and switched to another EGFR TKI after 
LMC occurrence. The other 16 patients received EGFR TKIs after 
LMC diagnoses. All the patients received intrathecal chemotherapy, 
including methotrexate, and six of them were treated with combined 
whole-brain radiotherapy. Gefitinib and erlotinib were administered 
to 11 and 14 patients, respectively. Ten patients had LMC controlled 
with cytologic negative conversion, whereas in 15 patients, cyto-
logical clearance of the cerebrospinal fluid could not be achieved. 
Patients treated with erlotinib showed better cytologic conversion 
rate of LMC than those with gefitinib (64.3% [9 of 14] in the erlo-
tinib arm versus 9.1% [1 of 11] in the gefitinib arm; p = 0.012).
Conclusion: This study suggested that erlotinib had better control 
rate for LMC in NSCLC than gefitinib. Further prospective study is 
warranted.
Key Words: Leptomeningeal carcinomatosis, Gefitinib, Erlotinib.
(J Thorac Oncol. 2013;8: 1069-1074)
Non–small-cell lung cancer (NSCLC) patients with central nervous system (CNS) involvement have poor prognosis 
and deteriorated quality of life.1 Approximately 40% of NSCLC 
patients will have brain parenchymal metastases and 5% will 
develop leptomeningeal carcinomatosis (LMC).1,2 Several ther-
apeutic options, including whole-brain radiotherapy (WBRT) 
and intrathecal (IT) chemotherapy, could be applied to manage 
LMC. However, the efficacies are not satisfactory.3 Systemic 
chemotherapeutic agents that cannot easily penetrate the blood–
brain barrier (BBB) have limitations in controlling the malig-
nant cells inside the leptomeninges. WBRT has been suggested 
as not being particularly beneficial to survival of NSCLC 
patients with LMC.4 Although methotrexate and cytosine arabi-
noside have been major components of IT chemotherapy, these 
agents are not particularly effective for NSCLC.3
Because improvement of survival was proven by antago-
nizing epidermal growth factor receptor (EGFR) in subgroups 
of NSCLC patients with EGFR mutations,5 EGFR tyrosine 
kinase inhibitors (TKIs) have been indicated as the first choice 
of chemotherapy for those patients. However, penetration of 
the BBB has also been an issue with EGFR TKIs. Several ret-
rospective studies have reported the effectiveness of EGFR 
TKIs in treatment of LMC from NSCLC with EGFR muta-
tions.6–9 Erlotinib, an EGFR TKI, may have better penetration 
across the BBB, and a higher cerebrospinal fluid (CSF) con-
centration, than gefitinib, another EGFR TKI.10 There is still 
no conclusive evidence as to which EGFR TKI is more effec-
tive for LMC from NSCLC, erlotinib or gefitinib. The purpose 
of this study was to assess efficacies of erlotinib and gefitinib 
in the management of LMC from NSCLC by comparing the 
cytologic negative conversion rates of the CSF in both agents.
PATIENTS AND METHODS
Patients and Treatment
We reviewed the medical records of 25 patients, who 
were diagnosed with LMC from NSCLC, and were treated with 
EGFR TKIs at Seoul National University Hospital between 
2004 and 2012. Two EGFR TKIs, erlotinib (150 mg/day) and 
gefitinib (250 mg/day) were applied. The choice of the type 
of EGFR TKI was determined by the attending physician’s 
decision. Nine of 25 patients had been using one of the two 
EGFR TKIs at the time of LMC diagnosis and had added 
other treatment modalities for LMC without discontinuation 
of the EGFR TKI. Among these nine patients, three changed 
their EGFR TKI to another type of EGFR TKI after LMC 
occurrence. The remaining 16 patients were introduced to 
EGFR TKI after LMC diagnosis.
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Response Evaluation
The primary objective of this study was comparison of 
efficacies between erlotinib and gefitinib with LMC controls 
and cytologic negative conversion rates of the CSF. LMC was 
defined as the cytologic identification of malignant cells in 
the CSF. Control of LMC was evaluated by cytologic find-
ings of the CSF. Cytologic negative conversion was defined 
as the absence of malignant cells in the CSF three times in 
succession. All the patients received IT chemotherapy, includ-
ing methotrexate, and cytologic examination of the CSF was 
performed before every IT injection. Along with responses to 
LMC treatment, objective responses to systemic chemother-
apy were also assessed by the Response Evaluation Criteria in 
Solid Tumors.11
Statistical Analysis
Statistical analyses of categorical variables were per-
formed using Pearson’s χ2 test or Fisher’s exact test, where 
appropriate. Multivariate logistic regression analyses were 
performed using statistically significant variables in univariate 
analyses and characteristics of individual malignancy, includ-
ing EGFR mutation and brain parenchymal metastases status. 
A two-sided p value less than 0.05 was considered statistically 
significant. Statistical analyses were performed using SPSS 
19.0 statistical software (IBM Corporation, Armonk, NY). 
This study was approved by the Institutional Review Board 
of Seoul National University Hospital (approval number: 
H-1210-067-434).
RESULTS
Baseline Characteristics
The characteristics of the 25 patients are summarized 
in Table 1. Erlotinib was prescribed to 14 patients to man-
age LMC from NSCLC, and gefitinib was prescribed to 11 
patients. The median age at diagnosis was 58 years (range, 
44–70 years) in the erlotinib arm, and 49 years (range, 36–
70 years) in the gefitinib arm. All patients in the erlotinib 
arm had adenocarcinoma; in the gefitinib arm nine patients 
(81.8%) had adenocarcinoma, and two patients (18.2%) had 
unspecified non–small-cell carcinoma. In the erlotinib arm, 
exon 21 point mutations and exon 19 deletional mutations 
existed in five patients each, whereas in the gefitinib arm, 
four patients (36.3%) had point-mutated exon 21 and three 
patients (27.3%) had deleted exon 19. Three patients (21.4%) 
who were prescribed erlotinib had wild-type EGFR, and none 
of the patients who received gefitinib had wild-type EGFR. 
Among patients who were included in the erlotinib arm, three 
patients had been using gefitinib and shifted to erlotinib on 
LMC occurrence; and another 11 patients received erlotinib 
as their first EGFR TKI after detection of LMC. In the gefi-
tinib arm, six patients received gefitinib before and after LMC 
diagnoses without interruption, and another five patients were 
introduced to gefitinib as the start of the EGFR TKI.
Treatment of LMC
For the treatment of LMC, 14 patients received erlo-
tinib; and 11 patients received gefitinib. All 25 patients 
TABLE 1.  Baseline Characteristics
Characteristics Erlotinib Gefitinib p
No. of patients 14 11
Median age at diagnosis 58 (range,  
44–70 yr)
49 (range,  
36–70 yr)
Sex 1.000
 Male 4 (28.6%) 3 (27.3%)
 Female 10 (71.4%) 8 (72.7%)
Smoking status 1.000
 Never-smoker 10 (71.4%) 9 (81.8%)
 Ex-smoker 1 (7.1%) 0 (0.0%)
 Current smoker 3 (21.4%) 2 (18.2%)
ECOG performance status 0.580
 0–1 7 (50.0%) 8 (72.7%)
 2 5 (35.7%) 3 (27.3%)
 3–4 2 (14.3%) 0 (0.0%)
Histology 0.183
 Adenocarcinoma 14 (100.0%) 9 (81.8%)
 NSCLC NOS 0 (0.0%) 2 (18.2%)
EGFR mutation status 0.247
 Exon 21 mutation 5 (35.7%) 4 (36.4%)
 Exon 19 deletion 5 (35.7%) 3 (27.3%)
 Wild-type 3 (21.4%) 0 (0.0%)
 Unknown 1 (7.1%) 4 (36.4%)
Presentation of LMC 1.000
 Metachronousa 7 (50.0%) 6 (54.5%)
 Synchronousb 7 (50.0%) 5 (45.5%)
Coexisting brain parenchymal  
metastasis
0.341
 Present 10 (71.4%) 10 (90.9%)
 Absent 4 (28.6%) 1 (9.1%)
Whole-brain radiotherapy 1.000
 Yes 3 (21.4%) 3 (27.3%)
 No 11 (78.6%) 8 (72.7%)
Intrathecal chemotherapy 0.565
 Methotrexate 13 (92.9%) 9 (81.8%)
 Triplec 1 (7.1%) 2 (18.2%)
EGFR TKIs 0.115
 Continuous before  
 LMC
3 (21.4%) 6 (54.5%)
 Introduction after LMC 11 (78.6%) 5 (45.5%)
Previous lines of  
chemotherapy
1.000
 0 4 (28.6%) 3 (27.3%)
 1 4 (28.6%) 4 (36.4%)
 2 4 (28.6%) 3 (27.3%)
 >2 2 (14.3%) 1 (9.1%)
aMetachronous LMC is defined as LMC diagnosed more than 6 months after NSCLC 
diagnosis.
bSynchronous LMC is defined as LMC diagnosed within 6 months after NSCLC 
diagnosis.
cThe triple intrathecal chemotherapy regimen is consisted of methotrexate, 
cytarabine, and hydrocortisone.
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ECOG PS, 
Eastern Cooperative Oncology Group performance status; NSCLC, non-small-cell lung 
cancer; NOS, not otherwise specified; LMC, leptomeningeal carcinomatosis.
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underwent combined IT chemotherapy including methotrex-
ate. Thirteen patients in the erlotinib group and nine patients 
in the gefitinib group received IT methotrexate single, and 
one and two patients received an IT triple regimen (metho-
trexate/cytarabine/hydrocortisone), respectively. Coexisting 
brain parenchymal metastases existed in more than two thirds 
of the patients, and the number of patients who were treated 
with WBRT was less than one third in both arms. Details of 
the clinical factors and treatment modalities of all patients are 
summarized in Table 2.
Clinical Outcome for LMC
Ten patients had LMC controlled with cytologic nega-
tive conversion, whereas 15 did not have a confirmed CSF 
clear-up after at least three consecutive CSF analyses. Nine 
patients had already been using EGFR TKIs before the diag-
nosis of LMC and two (22.2%) of those patients achieved 
cytologic negative conversion, whereas seven (77.8%) did 
not attain the cleared CSF. Among the 16 patients who were 
introduced to EGFR TKIs after the detection of LMC, the 
number of patients, who could acquire cytologic negative 
conversion, and those who could not were eight (50.0%) 
in both groups. Table 3 exhibits cytologic negative conver-
sion rates along with each agent. Among the patients who 
received erlotinib, 64.3% of patients (n = 9) obtained cyto-
logic negative conversion; However, for the patients who 
were given gefitinib, the cytologic negative conversion rate 
was only 9.1% (n = 1; p = 0.012). Among the patients who 
had already been using EGFR TKIs before LMC, the number 
of those who achieved cytologic negative conversion with 
erlotinib and gefitinib were 16.7% (n = 1) and 33.3% (n = 1), 
respectively. Among the patients who received EGFR TKIs 
after LMC detection, 72.7% (n = 8) of the patients obtained 
cytologic negative conversion with erlotinib, whereas none 
of the patients with gefitinib achieved clear CSF. The effects 
of other treatment modalities on cytologic conversion were 
statistically insignificant (Table 3). In multivariate logistic 
regression analysis, only type of EGFR TKI was an inde-
pendent predictor for cytologic negative conversion of CSF 
(Table 4). From LMC diagnosis to death, patients with gefi-
tinib showed 4.4 months of overall survival (OS), whereas 
patients who received erlotinib had 9.5 months of survival 
duration. However, the survival analysis was not statistically 
significant (p = 0.960).
DISCUSSION
This study suggested that erlotinib might be more 
effective at controlling LMC from NSCLC than gefitinib. In 
this study, cytologic negative conversion rates were higher in 
erlotinib than in gefitinib (64.3% versus 9.1%; p = 0.012)
In 2004, gefitinib was shown to be dramatically effi-
cacious in NSCLC with EGFR mutations.5,12 The throne of 
EGFR TKIs as the treatment of choice in the field of NSCLC 
harboring EGFR mutations is solid for now. However, despite 
remarkable improvement with EGFR TKIs, the standard treat-
ment guidelines for LMC from NSCLC have still not been 
established. The efficacies of current treatment modalities are 
not satisfactory.3
LMC is one of the gravest complications of NSCLC. 
Patients with metastatic malignant cells inside the 
subarachnoid space suffer from a short duration of survival 
and devastated quality of life.13 According to several studies, 
patients who had an initial response to gefitinib tended to 
have the CNS as a frequent recurrent site, independent of 
the primary lung lesions.14 A relatively increased prevalence 
of LMC from NSCLC after introduction of gefitinib was 
suggested as a partial result of improvements in systemic 
control with gefitinib4 because gefitinib does not seem to be 
able to penetrate the BBB completely and reach malignant 
cells inside the CSF.15,16
The comparison of erlotinib and gefitinib in treatment 
of LMC from NSCLC has not been performed until now. In 
our study, we retrospectively analyzed cytologic negative con-
version rates of the CSF in patients who used erlotinib or gefi-
tinib to evaluate efficacies of both agents in the treatment of 
LMC from NSCLC. Patients who were treated with erlotinib 
showed higher cytologic negative conversion rates. Patients 
who had brain parenchymal metastases and received IT che-
motherapy and WBRT were evenly distributed in both groups. 
The primary endpoint of this study was cytologic negative 
conversion rates of the CSF because patients who obtained 
the cytologic negative conversion of the CSF can achieve a 
longer survival and a better quality of life.17
Recently, several studies have reported that EGFR 
TKIs could be a considered treatment option for patients with 
LMC from NSCLC.6–8 Yi et al.7 reported that 11 patients who 
were treated with erlotinib and gefitinib had overt clinical 
improvement. Park et al.6 showed that patients who were 
treated with EGFR TKIs, in addition to IT chemotherapy, had 
prolonged OS compared with patients who did not receive 
EGFR TKIs. Several reports have suggested that erlotinib 
could be a more proper therapeutic agent for patients with 
LMC from NSCLC.16,18,19 Some studies have proposed that 
erlotinib might be more effective in controlling LMC from 
NSCLC than gefitinib.10 The background explanation of 
these studies is the difference in routine dosages between the 
two drugs. The approved daily dosage of erlotinib (150 mg/
day) is equal to the maximum tolerated dosage (MTD),20 in 
contrast the daily dosage of gefitinib is set at 250 mg/day, 
which is approximately one third of the MTD (700 mg/day) of 
this drug.21 Even though the MTD of gefitinib is 250 mg/day, 
increasing the gefitinib dosage up to 1000 mg/day, might help 
in achieving higher CSF levels of gefitinib, and a remarkable 
improvement of LMC with reversible toxicities.9 Higher 
serum concentrations of EGFR TKIs could be carried beyond 
the BBB.10 Gefitinib-naive malignant cells in the CNS have 
not developed a resistance mechanism for EGFR TKIs, thus 
erlotinib transported beyond the BBB in a relatively higher 
serum concentration than gefitinib may remain effective 
against these metastatic tumor cells.8
Our study has some limitations. First, this study was a 
retrospective study. The choice and the starting juncture of 
EGFR TKIs were made on the basis of the physicians’ clini-
cal decisions, which resulted in the uneven distribution of 
patients in terms of who received the first EGFR TKIs after 
LMC, and who used EGFR TKIs continuously before and 
after LMC diagnosis. However, various confounding factors 
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were not statistically different in both arms. Second, because 
the sample size was not large, the comparison of the OS after 
LMC between the erlotinib group and the gefitinib group was 
not statistically significant (p = 0.960). However, the survival 
duration after LMC diagnosis in the erlotinib group was twice 
that in the gefitinib group (9.5 months versus 4.4 months; 
p = 0.960). Despite these limitations, the characteristics of 
patients were homogenous. To our best knowledge, this is the 
first study that has compared efficacies between gefitinib and 
erlotinib in the management of LMC from NSCLC.
In LMC from NSCLC, erlotinib was more effective in 
obtaining cytologic negative conversion of the CSF than gefi-
tinib for a subgroup of patients. The results of this study sug-
gest that erlotinib provides better control of LMC in NSCLC, 
than gefitinib. Further prospective study is warranted.
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